State Street’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,139,662
| Closed | -$113M | – | 4274 |
|
|
2026
Q1 | $113M | Buy |
2,139,662
+363,740
| +20% | +$14.9M | ﹤0.01% | 1311 |
|
|
2025
Q4 | $71.7M | Buy |
1,775,922
+170,229
| +11% | +$3.93M | ﹤0.01% | 1538 |
|
|
2025
Q3 | $12.1M | Buy |
1,605,693
+232,252
| +17% | +$1.48M | ﹤0.01% | 2534 |
|
|
2025
Q2 | $5.12M | Buy |
1,373,441
+48,924
| +4% | +$153K | ﹤0.01% | 2930 |
|
|
2025
Q1 | $3.66M | Buy |
1,324,517
+37,474
| +3% | +$153K | ﹤0.01% | 3003 |
|
|
2024
Q4 | $7.13M | Buy |
1,287,043
+170,052
| +15% | +$1.15M | ﹤0.01% | 2803 |
|
|
2024
Q3 | $9.32M | Sell |
1,116,991
-59,842
| -5% | -$492K | ﹤0.01% | 2647 |
|
|
2024
Q2 | $8.01M | Buy |
1,176,833
+271,339
| +30% | +$1.64M | ﹤0.01% | 2694 |
|
|
2024
Q1 | $5.94M | Buy |
905,494
+18,615
| +2% | +$122K | ﹤0.01% | 2858 |
|
|
2023
Q4 | $5.76M | Buy |
886,879
+8,680
| +1% | +$45.9K | ﹤0.01% | 2883 |
|
|
2023
Q3 | $4.42M | Buy |
878,199
+57,477
| +7% | +$365K | ﹤0.01% | 2978 |
|
|
2023
Q2 | $7.18M | Buy |
820,722
+701,683
| +589% | +$8.18M | ﹤0.01% | 2813 |
|
|
2023
Q1 | $1.41M | Buy |
119,039
+59,502
| +100% | +$569K | ﹤0.01% | 3433 |
|
|
2022
Q4 | $606K | Buy |
59,537
+17,500
| +42% | +$116K | ﹤0.01% | 3702 |
|
|
2022
Q3 | $248K | Buy |
42,037
+22,200
| +112% | +$82.5K | ﹤0.01% | 4043 |
|
|
2022
Q2 | $49K | Sell |
19,837
-143,400
| -88% | -$286K | ﹤0.01% | 4727 |
|
|
2022
Q1 | $485K | Buy |
163,237
+1,218
| +0.8% | +$5.2K | ﹤0.01% | 4061 |
|
|
2021
Q4 | $1.15M | Buy |
162,019
+11,679
| +8% | +$97.3K | ﹤0.01% | 3783 |
|
|
2021
Q3 | $1.57M | Buy |
150,340
+21,637
| +17% | +$224K | ﹤0.01% | 3676 |
|
|
2021
Q2 | $1.58M | Buy |
128,703
+30,056
| +30% | +$512K | ﹤0.01% | 3584 |
|
|
2021
Q1 | $2.17M | Buy |
+98,647
| New | +$2.16M | ﹤0.01% | 3408 |
|
Other funds holding TERN
State Street's TERN Position: Q2 2026 in Review
State Street sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,139,662 shares — an estimated $113M sold.
State Street first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $113M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- State Street reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- State Street sold 2,139,662 Terns Pharmaceuticals shares in Q2 2026, an estimated $113M.
- State Street first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- State Street's Terns Pharmaceuticals position peaked at $113M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.